[Special Stock] HLB Gains for Second Day Following US FDA Recommendation to Reapply for Liver Cancer Drug Review
HLB has been on the rise for the second consecutive day. This is attributed to news that the U.S. Food and Drug Administration (FDA) has recommended the submission of a reexamination application for Hanseo Pharmaceutical's camrelizumab, a combination drug with HLB's liver cancer new drug 'Rivoceranib.'
As of 10:22 AM on the 4th, HLB is trading at 81,700 KRW, up 6.51% compared to the previous day.
On the 2nd (local time), HLB announced that during a meeting in the U.S. to resume the approval review of the liver cancer new drug, the FDA strongly recommended submitting a reexamination application. The FDA delivered an official document (PAL·Post Action) regarding the CMC (Chemistry, Manufacturing, and Controls) issues of camrelizumab.
Hot Picks Today
"An Insult to All Women": Female Athletes Outraged Over Ad with 37 Million Views in Four Days
- "Bought Raw Materials at 1,500 Won, Selling at 1,300 Won"—Exchange Rate Plunge Casts a Shadow as Export Giants Face Third-Quarter Alarm
- "Representing the Rights of 961,000 Korean Residents in Japan"...Busan Native Jaeuk Jung Founds Japan’s First Naturalized Citizen-Led Party
- Police Give 70,000 Won of Their Own Money to Homeless Man in His 40s Who Stole Two Bags of Potato Rice Cakes Out of Hunger
- "Weight Dropped Rapidly... Anyone Can Get It Easily": Why a Woman in Her 20s Quit Mountzaro After Losing 6kg in a Month
The meeting included HLB, HLB's subsidiary Elevate Therapeutics, and Hanseo Pharmaceutical. According to HLB, the document contained the FDA's position that Hanseo Pharmaceutical has no additional documents to submit related to the camrelizumab CMC inspection. Hanseo Pharmaceutical can submit the Biologics License Application (BLA) to the FDA reflecting the supplementary CMC materials already submitted twice.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
